Ciltacabtagen-Autoleucel
Ciltacabtagen-Autoleucel | |
---|---|
Term | Ciltacabtagen-Autoleucel |
Short definition | Ciltacabtagen-Autoleucel - (pronounced) (SIL-tuh-KAB-tuh-jeen AW-toh-LOO-sel) drug used to treat adults with multiple myeloma that has come back or failed to improve after treatment with at least four other cancer therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. Ciltacabtagene Autoleucel is made using a patient's T cells (a type of cell in the immune system). |
Type | Cancer terms |
Specialty | Oncology |
Language | English |
Source | NCI |
Comments |
Ciltacabtagen-Autoleucel - (pronounced) (SIL-tuh-KAB-tuh-jeen AW-toh-LOO-sel) drug used to treat adults with multiple myeloma that has come back or failed to improve after treatment with at least four other cancer therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. Ciltacabtagene Autoleucel is made using a patient's T cells (a type of cell in the immune system). A gene for a special receptor called the chimeric antigen receptor (CAR) is added to the T cells in the laboratory. Large numbers of these modified T cells, known as CAR T cells, are cultivated in the laboratory and given to the patient by infusion. Ciltacabtagene Autoleucel attaches to a protein called BCMA, which is found on myeloma cells and some types of immune cells. This helps the body's immune system kill cancer cells. Ciltacabtagene Autoleucel is a form of CAR T cell therapy. Also called Carvykti
External links
- Medical encyclopedia article on Ciltacabtagen-Autoleucel
- Wikipedia's article - Ciltacabtagen-Autoleucel
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski